Trial Profile
A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-181; MK-3475-181/KEYNOTE-181
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 25 Mar 2022 Status changed from active, no longer recruiting to completed.
- 25 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Dec 2021 Planned End Date changed from 31 Dec 2021 to 14 Mar 2022.